Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
| Revenue | $2,355,300,000 |
| Net Income | $341,300,000 |
| Free Cash Flow | $557,200,000 |
| Book Value / Share | $25.79 |
| Total Liabilities | $1,129,000,000 |
| Total Equity | $2,589,700,000 |
| Debt / Equity | 0.18 |
| Current Ratio | 3.40 |
| Interest Coverage | 4.51 |
| Working Capital | $1,217,000,000 |
Core multiples and valuation signals — useful to compare vs peers.
| P/E (TTM) | 40.15 |
| Industry P/E | N/A |
| Forward P/E | 22.18 |
| P/B | 5.29 |
| Price / Sales | 5.82 |
| P / FCF | 24.60 |
| EV / EBITDA | 21.77 |
| Graham Number | $44.42 |
| DCF (placeholder) | — |
| Gross Margin | 98.56% |
| Operating Margin | 24.22% |
| Net Margin | 14.49% |
| ROIC | 12.48% |
| Asset Turnover | 0.63 |
| RSI (14) | 46.54 |
| SMA 50 | 137.88 |
| SMA 200 | 126.55 |
| MACD | -0.65 |
| Signal | BULLISH |
| Name | Title |
|---|---|
| Mr. Kyle W. Gano Ph.D. | CEO & Director (1973) |
| Mr. Matthew C. Abernethy CPA | Chief Financial Officer (1980) |
| Dr. Jude Onyia Ph.D. | Chief Scientific Officer (1964) |
| Mr. Eric S. Benevich | Chief Commercial Officer (1965) |
| Dr. Eiry Wyn Roberts M.D. | Strategic Advisor (1964) |
| Dr. Wylie W. Vale Ph.D. | Co-Founder (1942) |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder of Neurocrine (1948) |
| Mr. Lewis Choi | Chief Information Officer (—) |
No news available for this company.